ES2629309T3 - Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora - Google Patents

Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora Download PDF

Info

Publication number
ES2629309T3
ES2629309T3 ES09700368.5T ES09700368T ES2629309T3 ES 2629309 T3 ES2629309 T3 ES 2629309T3 ES 09700368 T ES09700368 T ES 09700368T ES 2629309 T3 ES2629309 T3 ES 2629309T3
Authority
ES
Spain
Prior art keywords
treatment
formulations
antitumor
immunosuppressive therapy
mucositis induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09700368.5T
Other languages
English (en)
Inventor
Ezio Bombardelli
Gabriele Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Application granted granted Critical
Publication of ES2629309T3 publication Critical patent/ES2629309T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60S—SERVICING, CLEANING, REPAIRING, SUPPORTING, LIFTING, OR MANOEUVRING OF VEHICLES, NOT OTHERWISE PROVIDED FOR
    • B60S3/00—Vehicle cleaning apparatus not integral with vehicles
    • B60S3/04—Vehicle cleaning apparatus not integral with vehicles for exteriors of land vehicles
    • B60S3/06—Vehicle cleaning apparatus not integral with vehicles for exteriors of land vehicles with rotary bodies contacting the vehicle
    • B60S3/063—Vehicle cleaning apparatus not integral with vehicles for exteriors of land vehicles with rotary bodies contacting the vehicle the axis of rotation being approximately vertical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mechanical Engineering (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Formulaciones que contienen sanguinarina o queleritrina en forma de sales de ácido luteico en mezcla con vehículos y/o excipientes adecuados para su uso en el tratamiento y/o la prevención de la mucositis.

Description

imagen1
imagen2
imagen3

Claims (1)

  1. imagen1
ES09700368.5T 2008-01-11 2009-01-08 Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora Active ES2629309T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000038A ITMI20080038A1 (it) 2008-01-11 2008-01-11 Formulazioni per il trattamento di mucositi indotte da terapia antitumorale o immunosoppressiva
ITMI20080038 2008-01-11
PCT/EP2009/000050 WO2009087091A2 (en) 2008-01-11 2009-01-08 Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy

Publications (1)

Publication Number Publication Date
ES2629309T3 true ES2629309T3 (es) 2017-08-08

Family

ID=40290063

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09700368.5T Active ES2629309T3 (es) 2008-01-11 2009-01-08 Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora

Country Status (17)

Country Link
US (1) US8940338B2 (es)
EP (1) EP2231158B1 (es)
JP (1) JP5357896B2 (es)
KR (1) KR20100100953A (es)
CN (1) CN101917997A (es)
AU (1) AU2009203819B2 (es)
CA (1) CA2711840C (es)
DK (1) DK2231158T3 (es)
ES (1) ES2629309T3 (es)
HU (1) HUE035036T2 (es)
IL (1) IL206881A (es)
IT (1) ITMI20080038A1 (es)
PL (1) PL2231158T3 (es)
PT (1) PT2231158T (es)
RU (1) RU2460535C2 (es)
SI (1) SI2231158T1 (es)
WO (1) WO2009087091A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011825A2 (en) 2005-07-19 2007-01-25 Texas Enterosorbent, Inc. Preservative and additive for food and feed
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
US9597313B2 (en) 2006-06-27 2017-03-21 Timothy D. Phillips Composition and methods for the enterosorption and management of toxins
CN101904849A (zh) * 2010-08-19 2010-12-08 苏州大学 血根碱制备肿瘤放射治疗增敏药物的应用
WO2013059827A1 (en) * 2011-10-20 2013-04-25 Salient Pharmaceuticals, Inc. Methods and compositions for treating mucositis
AT515336A1 (de) * 2014-02-03 2015-08-15 Roth Hermann Dr Vermeidung oxidativer Prozesse und oxidativem Stress
JP7096332B2 (ja) * 2017-07-31 2022-07-05 ムコサ イノバティオンズ，エセ エレ 腫瘍処置誘導性の経口胃腸粘膜炎の予防および／または処置における使用のための組成物
KR102893442B1 (ko) * 2022-12-23 2025-12-01 가톨릭대학교 산학협력단 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254321B (it) * 1992-04-10 1995-09-14 Kemiprogress S R L Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale.
JP2000109428A (ja) * 1998-10-05 2000-04-18 Taisho Pharmaceut Co Ltd 咽頭粘膜用組成物
ITMI20042414A1 (it) 2004-12-17 2005-03-17 Indena Spa Formulazione per il trattamento di affezioni delle prime vie respiratorie
US7491414B2 (en) * 2005-10-12 2009-02-17 Gaia Herbs, Inc. Anti-inflammatory substances extracted from Echinacea
EP1882473A1 (en) * 2006-07-28 2008-01-30 Indena S.P.A. Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono

Also Published As

Publication number Publication date
US20100284945A1 (en) 2010-11-11
EP2231158A2 (en) 2010-09-29
ITMI20080038A1 (it) 2009-07-12
SI2231158T1 (sl) 2017-06-30
KR20100100953A (ko) 2010-09-15
WO2009087091A2 (en) 2009-07-16
RU2460535C2 (ru) 2012-09-10
CA2711840A1 (en) 2009-07-16
AU2009203819A1 (en) 2009-07-16
US8940338B2 (en) 2015-01-27
DK2231158T3 (en) 2017-06-12
RU2010128171A (ru) 2012-01-20
JP5357896B2 (ja) 2013-12-04
EP2231158B1 (en) 2017-04-05
WO2009087091A3 (en) 2009-11-26
WO2009087091A8 (en) 2009-10-08
AU2009203819B2 (en) 2014-07-31
IL206881A (en) 2015-09-24
CA2711840C (en) 2014-02-18
PT2231158T (pt) 2017-07-03
IL206881A0 (en) 2010-12-30
CN101917997A (zh) 2010-12-15
PL2231158T3 (pl) 2017-09-29
HUE035036T2 (en) 2018-05-02
JP2011509270A (ja) 2011-03-24

Similar Documents

Publication Publication Date Title
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2478820T3 (es) Tratamiento de degeneración macular
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2496669T3 (es) Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen
ES2527454T3 (es) El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
DOP2014000260A (es) Compuestos d-aminoácidos para enfermedad hepática
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
MX2009013332A (es) Inhibidores de ire-1 alfa.
CL2013002003A1 (es) Compuestos derivados de 1, 2, 4-triazolo [4,3-a] quinoxalina, inhibidores de pde2 y/o 10; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para en el trastamiento de enfermedades del snc
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
ES2528366T3 (es) Citicolina para el tratamiento del glaucoma
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
MX2024006769A (es) Compuestos y usos de los mismos.
CL2019003293A1 (es) Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para su uso en el tratamiento de tumores sólidos.
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
ES2534911T3 (es) Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
WO2009087091A8 (en) Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy
CL2011001258A1 (es) Sales de adicion de acido citrico de (r)-5-((e)-2-pirrolidin-3-il vinil)pirimidina; formas polimorficas monocitrato; composicion farmaceutica que las comprende; y su uso en la prevencion o en el tratamiento del dolor, inflamacion o un trastorno del sistema nervioso central.
CL2010001421A1 (es) Uso de dronedarona en la preparacion de medicamentos utiles para la prevencion de fibrilacion o aleteo auricular persistentes.